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Abstract
Human Rhinovirus (HRV) is associated with acute exacerbations of chronic respiratory disease. In healthy individuals, innate
viral recognition pathways trigger release of molecules with direct anti-viral activities and pro-inflammatory mediators
which recruit immune cells to support viral clearance. Interleukin-1alpha (IL-1a), interleukin-1beta (IL-1b) and interleukin-18
(IL-18) have critical roles in the establishment of neutrophilic inflammation, which is commonly seen in airways viral
infection and thought to be detrimental in respiratory disease. We therefore investigated the roles of these molecules in
HRV infection of primary human epithelial cells. We found that all three cytokines were released from infected epithelia.
Release of these cytokines was not dependent on cell death, and only IL-1b and IL-18 release was dependent on caspase-1
catalytic activity. Blockade of IL-1 but not IL-18 signaling inhibited up-regulation of pro-inflammatory mediators and
neutrophil chemoattractants but had no effect on virus induced production of interferons and interferon-inducible genes,
measured at both mRNA and protein level. Similar level of virus mRNA was detected with and without IL-1RI blockade.
Hence IL-1 signaling, potentially involving both IL-1b and IL-1a, downstream of viral recognition plays a key role in induction
of pro-inflammatory signals and potentially in recruitment and activation of immune cells in response to viral infection
instigated by the epithelial cells, whilst not participating in direct anti-viral responses.
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Introduction
Significant unmet medical need remains for the reduction of
frequent or severe acute exacerbations (AE) in patients with
chronic respiratory disease, such as chronic obstructive pulmonary
disease (COPD). Patients with moderate to severe COPD and a
history of exacerbations continue to have frequent and severe
exacerbations despite treatment, have a worse quality of life and
an increased risk of mortality [1,2,3,4]. Human rhinovirus (HRV)
is a very commonly detected virus at exacerbation [5,6], and has
been associated with higher AECOPD symptom scores [6]. Host
responses to rhinovirus appear aberrant in COPD patients [7] and
therefore further investigations into the mechanisms involved in
viral recognition and pro-inflammatory responses is required to
inform similar studies in AECOPD.
HRV is a non-enveloped single stranded RNA virus of the
Picornaviridae family which predominantly and initially infects cells
of the airways epithelium [8]. HRV serotypes are principally
major or minor group viruses which bind to intracellular adhesion
molecule-1 (ICAM-1) or low-density lipoprotein (LDL) receptor
respectively, and there is also a group of HRV-C viruses for which
the mode of infection is unknown [8]. Following HRV infection,
epithelial cells release inflammatory mediators which activate
lung-resident macrophages and together recruit immune cells
required for optimal viral clearance. These mediators include
those that amplify local inflammation (such as IL-1), mediate
specific patterns of leukocyte recruitment and activation (such as
IL-8, IP-10, IL-6) as well as those that initiate anti-viral defence
(such as interferons (IFN) IFNb, IFNl) [9].
Although much is known about the role of pattern recognition
receptors in host anti-viral defence, host recognition of HRV
infection is not yet fully understood. Rhinoviral detection involves
the pattern recognition receptors MDA-5, RIG I, TLR3, and
interferon-inducible elements [10] and also TLR7/8 [11], working
in a co-ordinated fashion. Unlike most cytokines, IL-1b and IL-18
are translated without a leader sequence, resulting in their
accumulation within the cytosol [12]. Activation of multi-protein
complexes known as inflammasomes, results in initiation of
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caspase-1 mediated cleavage of pro- IL-1b and pro-IL-18 into
their mature forms, allowing their secretion [13]. Antiviral
immunity involving the NLRP3, AIM-2 or RLRs, can result in
the assembly of inflammasomes, thus linking viral sensing with
release of IL-1b and IL-18 [14,15] although this has not been
specifically elaborated for HRV. In addition to viral nucleic acid
recognition, other pathogen-associated molecular patterns and
virally-induced signaling events can also contribute to the
inflammatory response. For example, activation of spleen tyrosine
kinase (Syk) downstream of ICAM binding of major group viruses
has been implicated with cytokine release after HRV infection
[16]. Increases in pro-inflammatory mediators are seen with
replication deficient virus, indicating rapid viral recognition
immediately following infection [17,18]. Knockdown of Syk
resulted in a partial reduction of IL-8 in response to HRV
infection, suggesting that multiple mechanisms of IL-8 induction
combine [16].
It is possible direct cell death following viral infection may
contribute to the inflammatory response. Both IL-1b and IL-18
can be processed to their active forms by several soluble proteolytic
enzymes if the pro-cytokines are released from the cytosol of cells
[19,20], for example upon uncontrolled forms of cell death or lysis.
Although IL-1a can be cleaved, such cleavage is not mediated by
caspase-1 and IL-1a does not need to be processed to be active,
but passive release of IL-1a from dead cells can induce
inflammatory processes in response to necrosis [21]. IL-1a and
IL-1b may recruit different myeloid cells at different stages of
sterile inflammation [22] suggesting that release of and response to
these related molecules can be substantially co-ordinated.
Given that IL-1a, IL-b and IL-18 are highly related cytokines,
we sought to understand their role in normal epithelial responses
to HRV with greater granularity. Although well understood that
IL-1 is an important cytokine in the establishment of inflamma-
tion, it is not known specifically whether host recognition of HRV
results in active or passive release of IL-1, whether caspase-1
activation is required and what the relative role of IL-1 and IL-18
are in amplifying specific epithelial cell responses. The production
of these cytokines was studied, with particular regard to caspase-1
processing and cell death, in response to HRV infection of primary
normal human bronchial epithelial cells. Protein and gene-
modulation of known components of anti-viral immunity were
investigated in the presence of inhibitors of signaling of these
cytokines with HRV infection.
Although release of active IL-1b and IL-18 was dependent on
viral entry and caspase-1 cleavage, IL-1a release was dependent
on viral entry, but not dependent on cell death or caspase-1
catalytic activity. A role for IL-1a in direct viral responses has on
the whole been overlooked until now. Whilst inhibition of IL-18 in
this assay system had no effect, blockade of IL-1RI had a clear
impact on classic pro-inflammatory responses of epithelial cells,
but did not impact interferon and interferon-inducible pathways,
and did not alter viral load.
Figure 1. HRV induces the release of IL-1a, IL-1b and IL-18 by NHBE cells. NHBE cells were infected with or without HRV14 (A and B) or
HRV1b (C). After 48 h the levels of IL-1a (A), IL-1b (A, B and C) and IL-18 (A) released into the media were measured by ELISA. In (B), some samples
were treated with an anti ICAM-1 antibody or an isotype control (both 1.33 mM) for the duration of the infection. Data is expressed as mean 6 SEM.
An * indicates a significant up-regulation in protein release, a # indicates there was a significant inhibition in protein release (***/# # # p,0.001,
**/# # p= 0.001–0.01, */# p=,0.05). N= 8 (A), 7 (B) or 4 (C). Untreated indicates cells were treated with medium alone.
doi:10.1371/journal.pone.0063365.g001
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Materials and Methods
Inhibitors
All inhibitors used were commercially available: anti-ICAM-1
mAb (clone 14C11 R&D Systems, Minneapolis, MN), YVAD
(VWR, Lutterworth, UK), BAX inhibitory peptideV5 (Sigma, St
Louis, MO), IL-18BPa-Fc chimera (R&D Systems, Abingdon,
UK), anakinra (commercially available KineretH, Amgen/Biovi-
trium).
HRV production
Virus was propagated by infection of Hela-H1 cells (American
Type Culture Collection (ATCC), LGC Standards, Teddington,
UK) with HRV14 (ATCC) for 48 h at 33uC in EMEM containing
2 mM L-Glutamine and 1% non essential amino acids (NEAA).
Virus-containing supernatant was collected, centrifuged, and virus
precipitated with 7% PEG6000 and 0.5 M NaCl at 4uC overnight.
Following precipitation virus was centrifuged and resuspended by
overnight incubation in PBS. This was then centrifuged, filtered
(0.22 mm Steriflip filter (Millipore, Watford, UK)) and concen-
trated (100,000 NMCO centrifugal filter device (AMICON,
Watford, UK)). During the concentration step buffer was
exchanged to fresh PBS in order to remove any contaminating
cytokines.
Median tissue culture infective dose (TCID50) of purified
HRV14 was determined by incubating Hela-Ohio cells (European
Collection of Cell Culture (ECACC), Porton Down, UK) (36104
cells seeded in a 96 well plate 24 h before infection) with 10 fold
serial dilutions of virus in MEM containing 100 units/ml of each
of penicillin and streptomycin, 1% NEAA, and 10% FCS
(Invitrogen, Paisley, UK). Cells were incubated with the virus for
6 days before they were fixed in 3.7% formaldehyde, and stained
for 10 minutes in 0.1% crystal violet. The mean absorbance of 100
scans at 600 nm was calculated per well. All wells with average
absorbance less than 80% of non-infected controls were consid-
ered to be infected. After scoring the number of infected wells (of a
maximum of 6 wells) at each titration of virus the Spearman
Karber method was used to calculate the TCID50 [23]. This was
then used to calculate the multiplicity of infection (MOI, the
number of infectious units/cell). Sample data and calculation is
shown in Table S1. Normal human bronchial epithelial (NHBE)
cell cytokine release measured at 48 h after 3 h viral incubation
was significantly different from uninfected cells at a low and higher
MOI (Figure S2) and was ICAM-1 dependent (Figure 1B). Based
on these data an MOI of 0.007 was used for all experiments.
Figure 2. HRV14 induces the release of the pro- and mature forms of IL-1b and IL-18. (A) NHBE cells were infected with or without HRV14
and the levels of IL-1b and pro-IL-1b released into the media after 48 hours was measured by ELISA. Untreated indicates cells were incubated with
medium alone. Data is expressed as mean6 SEM, an * indicates a significant up-regulation in protein release (IL-1b, p= 0.0168. pro-IL-1b, p= 0.0151.),
N=6. The levels of IL-18 in NHBE lysates (B) or media taken from NHBE cells (C) was measured by ELISA before and after treatment with rCaspase-1 in
order to detect the presence of pro-IL-18. The data in (B) is expressed as mean6 SEM and is a representative graph from 3 independent experiments,
the data in (C) is mean 6 SEM (N=3).
doi:10.1371/journal.pone.0063365.g002
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NHBE cell culture and infection
NHBE cells (Lonza, Zurich, SW) from 3 different donors were
cultured in bronchial epithelial basal medium (BEBM) containing
bronchial epithelial growth medium supplements (BEGM)
(Lonza). NHBE cells (passage 2) were seeded at a density of
1.26105/ml and incubated overnight. The next day, incubation
with virus and appropriate inhibitors progressed for 3 h at 33uC
before the virus-containing medium was replaced with BEGM
medium containing inhibitors alone. Cells were incubated for
48 h, unless indicated otherwise, before the media was collected
for mediator analysis by ELISA. If required for RNA extraction,
cells were washed in PBS, lysed in Qiazol (Qiagen, Crawley, UK)
and lysates stored at 280uC until processed.
Cytokine detection
All ELISA kits or detection/capture antibodies were purchased
from R&D Systems. Pro-IL-1b was measured using a Quantikine
ELISA kit according to manufacturer’s instructions. Interleukin-18
levels were determined using clones 125-25 and biotinylated 159-
12B as capture and detection antibodies respectively. DuosetTM
ELISA kits for IL-1a, IL-1b, IL-8, IL-6 and IP-10 were used
according to the manufacturer’s instructions except for a final
detection step modification to a dissociation-enhanced time-
resolved fluorescence method (DELFIA; all reagents Perkin Elmer,
Boston, MA). This utilised Europium-labeled streptavidin diluted
1/1000 in DELFIA assay buffer (in replacement for streptavidin-
HRP), and thorough washing and detection of time-resolved
fluorescence (e.g. by use of proprietary Enhancement solution) as
recommended by the manufacturer.
To detect pro-IL-18, media taken from infected NHBE cells or
lysates from permeabilised NHBE cells (PBS containing 0.1%
saponin and 16 complete protease inhibitors (Roche Applied
Science, Burgess Hill, UK) were incubated with 0.2 units of
recombinant Caspase-1 (Sigma Aldrich) in 1x reaction buffer
(50 mM NaCl, 50 mM Hepes (pH 7.3), 10 mM EDTA, 5%
glycerol, 0.1% CHAPS, 10 mM DTT) at 37uC for 1h. Samples
were then diluted 1/10 into PBS containing 1% BSA before IL-18
levels were measured as indicated above.
Cell death
Cell death was measured using a Cytotox-Glo kit (Promega,
UK), which utilises loss of membrane integrity to indicate cell
death, according to manufacturer’s instructions. Percentage cell
death was quantified by permeabilising parallel wells of NHBE
cells to define 100% cell death, as recommended in the kit.
RNA purification and gene analysis
RNA was purified from Qiazol lysed NHBE cells using a
mRNeasy mini kit (Qiagen) and cDNA was transcribed using a high
capacity RNA-to-cDNA kit (Applied Biosystems, USA), both
according to manufacturer’s instructions. IL-8 gene expression
was analysed using IL-8 (Hs99999034_m1) and 18s
(Hs99999901_s1) Taqman probes (Applied Biosystems) and ampli-
fied using Taqman Universal PCR MasterMix. A custom-made
microfluidic genecard (Applied Biosystems) was used to analyse the
effect of HRV14 infection on the host response, and contained a
panel of 45 genes of interest. Results were obtained for both
methods according to manufacturer’s instructions and using an
ABI7900HT real time PCR system (Applied Biosystems). Expres-
Figure 3. IL-1b and IL-18 are released by an active caspase-1 dependent event. NHBE cells were infected with or without HRV14 (A–C) in
the presence of the V5 Bax inhibitory peptide (B) or the caspase-1 inhibitor YVAD (C) at the indicated concentrations. A – indicates treatment with
the vehicle control. After 48 hours the level of cell death or cytokine release was measured. In B and C individual experiments were normalised by
expressing each replicate as a percentage of the median signal detected in the HRV treated sample. Data shown is the Mean percentage 6 SEM
(N= 3).
doi:10.1371/journal.pone.0063365.g003
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sion was analysed using the 22DDCt method (RQManager, Applied
Biosystems) using 18s as the internal control. For most genes the
data was expressed in relation to media control (uninfected cells)
samples at the indicated time point. For several genes (IFNB1, IL28A
and IL-29) there was no reproducible expression in the uninfected
cells; to analyse the effect of IL-1/IL-18 blockade, these genes used
sample treated with HRV14 alone as the reference condition. Viral
copy number was assessed as previously described [24].
Statistics
Where appropriate the data was analysed using Student’s T-test
or a One-way ANOVA with Bonferroni’s post test.
Supporting information
Materials and methods for data described in Supporting
Information is given in Materials and Methods S1.
Results
Human Rhinovirus infection of Normal Bronchial
Epithelial cells induces the release of IL-1 and IL-18
The release of IL-1a, IL-1b and IL-18 was evaluated on
rhinoviral infection of NHBE cells. A low MOI (0.007) of virus was
used for two reasons; firstly to mimic the in vivo infection of human
epithelium, occurring after inhalation of a very low number of
virus particles [25]; secondly, to limit cytopathic effects that may
occur following infection in vitro (see also Figure S2). After viral
infection, the amount of IL1a, IL-1b and IL-18 present in the cell
medium was measured by ELISA. A significant increase in the
amount of all three cytokines could be detected in the supernatant
of HRV-infected cells compared to control uninfected cells
(Figure 1A).
HRV14 binds ICAM-1 on the cell surface and uses this
adhesion molecule as a receptor to infect cells. Although we used
a purified stock of virus, thus reducing the chance of cytokine
contamination from cells used to produce the virus, we used a
neutralising anti-ICAM-1 antibody to demonstrate dependence
of the responses on viral binding. The release of IL-1b
(Figure 1B) and IL-8 (data not shown), were inhibited in the
presence of the anti-ICAM-1 antibody showing that infection of
NHBE cells by HRV14 was required to trigger a measurable
cytokine release.
The cytokine response is not specific to HRV14 as it could also
be observed with a minor group strain, HRV1b (Figure 1C).
Figure 4. IL-1 is required for the HRV dependent release of IL-6 and IL-8 but not IP-10 in NHBE cells. A) NHBE cells were infected with
HRV14 in the presence of a control IgG1 antibody (33 nM), IL-18BP-Fc (33 nM) or anakinra (10 nM). A – indicates no inhibitor treatment. The levels of
IL-6, IL-8, and IP-10 released into the media after 48 hours was assessed by ELISA (N= 5). Data is expressed as Mean 6 SEM, B) Levels of IL-8 mRNA
were determined in NHBE cells that were infected with HRV14 for 24 hours in the presence or absence of anakinra (10nM) (N= 3). – indicates no
treatment. The data is displayed as Mean (6 SEM) fold-expression in relation to the uninfected samples (22DDCt). An * indicates a significant increase
in protein release compared to untreated NHBE cells (*** p,0.001, ** p= 0.001–0.01), a # indicates a significant decrease in protein release/ mRNA
expression of HRV14 treated samples compared to the control (### p,0.001, ## p= 0.001–0.01) and ns indicates not significant (p.0.05).
doi:10.1371/journal.pone.0063365.g004
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IL-1b, IL-18 and their respective precursors are released
by HRV-infected cells
To determine what proportion of IL-1b and IL-18 was mature
processed cytokine, and/or whether pro-forms could be detected
in the supernatant of HRV-infected NHBE cells, we first assessed
2 different ELISA described as specific for either pro-IL-1b or IL-
1b respectively. As expected, the pro-IL-1b kit detected pro-IL-1b
and not mature IL-1b. However the IL-1b ELISA, whilst
accurately measuring recombinant IL-1b, was also able to detect
recombinant pro-IL-1b with 10% efficiency (data not shown). As
shown (Figure 2A), both pro- and mature forms of IL-1b could be
detected in the supernatant of HRV-infected cells obtained from 2
independent donors. A similar strategy could not be used to detect
pro-IL-18 as there is no specific ELISA available. Instead
recombinant caspase-1 was used to cleave the pro-peptide from
pro-IL-18 and an ELISA specific to the mature form of IL-18 was
then used to detect this newly processed mature IL-18. To validate
this approach, uninfected NHBE cell lysates were first incubated
with or without recombinant caspase-1 before the levels of IL-18
were determined, using the IL-18 ELISA. Mature IL-18 could be
detected in the lysate treated with recombinant caspase-1 whilst
there was no detectable signal in absence of enzyme. These data
are in keeping with previous results showing preformed pro-IL-18
in cells [26], and this result validates this approach as a way to
reveal the presence of pro-IL-18 in biological samples (Figure 2B).
We then treated supernatants from infected and uninfected NHBE
cells with recombinant caspase-1. As expected from experiments
reported in figure 1A, in absence of caspase-1, mature IL-18 could
be detected in the supernatants of HRV-infected cells (Figure 2C),
but not uninfected cells. The signal from infected cells was further
increased following caspase-1 treatment indicating that the
precursor form of IL-18 is also being released.
Virus-induced IL-1b and IL-18 release is an active process
depending on caspase-1 activation
Even at the relatively low MOI used in our experiments we
observed an increase in cell death after HRV14 infection (from 3%
to 12%) (Figure 3A). Therefore, we assessed the contribution of
cell death and/or caspase-1 activation on the release of IL-1b and
IL-18. Treatment with the BAX inhibitory peptide V5 during the
infection inhibited the induction of cell death by HRV14 but had
no effect on the release of IL-1b and IL-18 (Figure 3B). In
contrast to this, treatment with the caspase-1 inhibitor YVAD had
no effect on cell death but reduced the amount of extracellular
mature IL-1b and IL-18 detected (Figure 3C). IL-1a release was
not affected by the Bax V5 inhibitory peptide or the YVAD
inhibitor (Figure 3B–C). Infection of NHBE cells by HRV is thus
likely associated with recognition of viral products, oligomerisation
of the inflammasome resulting in caspase-1 activation and release
of mature IL-1b and IL-18, but also an alternative active process
resulting in IL-1a release.
Autocrine IL-1 signaling contributes significantly to IL-8
and IL-6 release, but does not alter viral load
Recombinant IL-1 is a potent activator of epithelial cells.
Having shown that infection of NHBE cells with HRV triggers the
release of IL-1a, IL-1b and IL-18, we investigated the extent of the
contribution of these cytokines to the release of other mediators by
autocrine mechanisms. NHBE cells were infected with HRV in the
presence or absence of anakinra (recombinant IL-1 receptor
antagonist), and Interleukin-18 binding protein (IL-18BP-Fc),
which interacts with IL-18 preventing its binding to IL-18R.
Addition of anakinra to the medium during and after viral
infection completely blocked the release of IL-6 and IL-8 without
significantly affecting IP-10 production (Figure 4A). In the same
experiment, addition of IL-18BP-Fc had no effect on the amount
of IL-6, IL-8 or IP-10 being produced by NHBE cells in response
to HRV infection (Figure 4A) (see also Figure S1B confirming
biological activity of IL-18BP-Fc). The inhibitory effect of
anakinra was also observed at the transcriptional levels since an
increase in IL-8 mRNA in HRV infected cells could not be
detected when anakinra was present (Figure 4B).
Since IL-1 has been shown to positively regulate the ICAM-1
surface expression it is possible that anakinra indirectly inhibited
viral entry through a reduction in ICAM-1 rather than having a
direct effect on cytokine production. We assessed viral copy
number by qPCR to understand this further. Virus was not
detected in untreated cells. Viral mRNA was detectable 24 h after
infection and appeared to be further increased at 48 h, although
this was not statistically significant. Anakinra had no significant
effect on these measured increases in detectable rhinovirus at both
time points (Figure 5).
Endogenous IL-1 signaling differently contributes to the
virally-induced transcription of gene families
We then investigated the consequences of neutralising IL-1R
signaling on a range of virally-induced mediators that potentially
play a role in the initiation of the immune response against the
virus. The effect of HRV infection on the expression of a panel of
genes was determined using a qPCR / genecard approach. These
genes were selected either because of their importance in IL-1 or
IL-18 pathways, or they encoded pro-inflammatory mediators,
type I interferons or interferon-inducible proteins, pattern
recognition receptors or signaling molecules that have been
previously reported to be important in viral responses by epithelial
cells. Among the pro-inflammatory mediators, a significant
Figure 5. Anakinra does not inhibit viral entry or replication.
NHBE cells were uninfected, infected with HRV14 or infected with
HRV14 in the presence of anakinra (10nM). After the indicated time RNA
was extracted and changes in viral copy number was assessed using
qRT-PCR. Data is expressed as Mean 6 SEM, an ns indicates there was
no significant difference (n.0.05) in copy number between samples
treated with HRV14 alone or HRV14 in the presence of anakinra.
doi:10.1371/journal.pone.0063365.g005
IL-1 Family Involvement in Rhinovirus Responses
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e63365
Table 1. IL-1 is required for the HRV-dependent release of pro-inflammatory cytokines and neutrophil chemoattractants but not T-
cell chemoattractants or members of the IFN family.
24 Hours 48 Hours
HRV HRV + anakinra HRV HRV + anakinra
Fold Change
vs
Medium Significance
% Inhibition
vs HRV Significance
Fold Change
vs Medium Significance
% Inhibition
vs HRV Significance
IL-1
Family
IL18 1.5 * 28 ns 0.8 ns 222 ns
IL18BP 1.8 ns 9 ns 0.8 ns 234 ns
IL18R1 1.2 ns 2 ns 1.2 ns 210 ns
IL1A 1.9 ns 50 ns 1.6 ns 41 ns
IL1B 2.4 ** 57 ## 1.6 ns 51 #
IL1R1 1.1 ns 1 ns 1.0 ns 22 ns
IL1RN 1.7 * 48 ## 1.3 ns 12 ns
Inflammatory
Mediators
CSF1 1.3 ns 14 ns 1.4 ns 16 ns
CSF2 4.2 *** 89 ### 4.5 *** 73 ###
CSF3 6.0 ** 92 ### 4.9 * 91 ###
CXCL2 3.6 *** 81 ### 2.4 *** 67 ###
CXCL5 7.6 ** 94 ### 6.8 * 92 ###
IL15 1.3 ns 30 ns 1.3 ns 270 ns
IL6 4.3 * 80 # 4.8 * 52 ns
IL8 10.4 *** 91 ### 5.6 *** 82 ###
TNF 6.0 ns 83 ns 4.6 ns 229 ns
TSLP 1.2 ns 4 ns 0.6 * 250 ns
Interferon
Pathway
CCL5 4.1 ns 16 ns 12.7 * 214 ns
CXCL10 21.8 * 47 ns 30.9 * 7 ns
CXCL11 6.6 ns 14 ns 24.9 * 251 ns
IFNAR1 1.1 ns 14 ns 1.1 ns 28 ns
IFNB1 UR - 0 ns UR - 224 ns
IL28A UR - 27 ns UR - 4 ns
IL29 UR - 40 ns UR - 19 ns
IRF3 0.8 ns 210 ns 1.3 ns 2 ns
IRF7 3.0 ns 229 ns 5.5 ns 228 ns
PPR IFIH1 2.3 ns 210 ns 6.0 ns 220 ns
LY96 1.1 ns 11 ns 0.6 ns 2 ns
RARRES3 1.0 ns 233 ns 1.2 ns 276 ns
TICAM1 1.9 ns 22 ns 1.5 ns 23 ns
TLR3 0.9 ns 233 ns 1.8 ns 283 ns
Other ICAM1 3.0 ** 74 ### 2.1 * 50 ns
MMP3 1.2 ns 17 ns 1.1 ns 212 ns
TIMP1 1.1 ns 216 ns 1.1 ns 221 ns
NHBE cells were uninfected, infected with HRV14 or infected with HRV14 in the presence of anakinra (10nM). After the indicated time RNA was extracted and changes in
mRNA was determined by a microfluidic genecard. The data is expressed as Mean (6 SEM) fold expression (22DDCt) in relation to the untreated controls. For some
mediators, while HRV14 increased mRNA expression there was no detectable expression in the untreated samples (this up-regulation is indicated by UR). To assess the
level of inhibition by anakinra these samples were expressed relative to the HRV14 treated samples (N=3). An * indicates a significant increase in mRNA expression on
treatment with HRV14 compared to untreated NHBE cells, a # indicates a significant decrease in mRNA expression when the infected NHBE cells were treated with
anakinra. An ns indicates not significant.
***/# # # p,0.001, **/# # p= 0.001–0.01, */# p=,0.05.
doi:10.1371/journal.pone.0063365.t001
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increase in mRNA for CSF2, CSF3, CXCL2, CXCL5, IL6, IL8,
and also IL1 and IL18 was observed 24 h after viral infection
(Table 1). For most of these genes an increased transcription was
still observed at the 48 h time point. Among the genes belonging
to the IFN pathway, CXCL10, IFNB1, IL28A and IL29 were
increased after 24 h of infection. A similar pattern was observed at
48 h except that CCL5 and CXCL11 were also significantly
increased. The fold change of mRNA for IFNB1, IL28A and IL29
could not be determined as their respective mRNA could not
reproducibly be detected in uninfected cells. Among the other
genes analysed in this study, ICAM1 and IL1RN were the only
ones significantly induced by HRV infection.
Whilst the gene up-regulation of the pro-inflammatory medi-
ators highlighted above was significantly decreased at both time
points by blockade of IL-1 signaling by anakinra (with the
exception of IL18), there was no significant effect on the
transcription of genes associated with the IFN pathway
(Table 1). A representative data set is shown in Figure 6 for
two genes belonging to the pro-inflammatory mediator family
(CSF2 and CXCL2) and 2 genes involved in the Type I interferon
response (CXCL11 and IFNB1).
Discussion
Acute exacerbations of asthma and COPD are often caused by
rhinovirus infection. Structural cells such as epithelial cells are the
first line of defence and play a key role in the initiation of the
immune response and IL-1 family members are produced very
early on during the development of the inflammatory cascade. In
the present study, we have shown that IL-1a, IL-1b and IL-18
were released by NHBE cells following HRV14 infection, and that
endogenous IL-1 signaling was essential for the induction and
production of a number of pro-inflammatory mediators in
response to the virus. Conversely, this autocrine and/or paracrine
IL-1 effect on infected epithelial cells did not contribute to virally-
induced IFN or IFN-driven responses.
The release of IL-1b following HRV infection of epithelial cells
in vitro has been previously described [27,28,29]. IL-1b has also
been measured in nasal secretions after experimental infection of
healthy volunteers with rhinovirus [30]. Nevertheless, in these
studies, no attempt has been made to distinguish between pro- and
cleaved forms of the cytokine, nor to measure IL-1a release. Stokes
et al [24] have demonstrated that autocrine generation of IL-1 may
be important in the inflammatory response to HRV, and that
knockdown of MyD88, which inhibits IL-1 signaling, can increase
viral load. However, this approach does not delineate the potential
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Figure 6. IL-1 is required for the HRV-dependent release of pro-inflammatory cytokines and neutrophil chemoattractants but not T-
cell chemoattractants or members of the IFN family. NHBE cells were uninfected, infected with HRV14 or infected with HRV14 in the presence
of anakinra (10 nM). After the indicated time RNA was extracted and changes in mRNA was determined by a microfluidic genecard. The data from
CSF2 (A), CXCL2 (B), CXCL11 (C) or IFNB1 (D) are presented and is expressed as Mean (6 SEM) fold expression (22DDCt) in relation to the untreated
controls (A–C) or the HRV14 treated samples (D) (N= 3). An * indicates a significant increase in mRNA expression on treatment with HRV14 compared
to untreated NHBE cells, a # indicates a significant decrease in mRNA expression when the infected NHBE cells were treated with anakinra. An ns
indicates not significant, (***/# # # p,0.001, **/# # p= 0.001–0.01, */# p=,0.05).
doi:10.1371/journal.pone.0063365.g006
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contribution of each IL-1RI-activating cytokine, and MyD88
knockdown would also inhibit additional responses e.g. those
mediated via TLR activation. Understanding the precise nature of
the IL-1 produced, and the contributions of key IL-1 family
members to the overall inflammatory response directed by the
epithelial cell, allows us to deduce whether we would see the same
outcome from inhibiting IL-1R1 signaling, preventing caspase 1
processing, or inhibiting either IL-1a or IL-1b separately. This
knowledge is clearly helpful in determining the optimal design of a
therapeutic intending to modulate virus induced inflammation via
blockade of the IL-1 pathway.
Consistent with classical activation of the inflammasome by viral
infection, significant levels of both IL-1b and IL-18 in their mature
forms were detected in the supernatant of infected cells, and
caspase-1 inhibition had an impact on this release. Mature IL-18
release by rhinovirus infected human bronchial epithelial cells has
only been recently reported [28]. The amount of mature IL-18
that we detected in the supernatant of infected cells was not only
higher than that reported by Shi et al, but also high in comparison
to what is generally released by lipopolysaccharide (LPS) treated
peripheral blood mononuclear cells (PBMCs) ([31] and our own
unpublished data). Additionally, the data described here suggests
that significant pre-stored IL-18 exists in an uncleaved pro-form in
epithelial cells. These data confirm HRV as a potential trigger for
significant release of mature IL-18, however inhibition of IL-18
mediated signaling had little impact on the measured autocrine
responses of the epithelial cell. Although this might initially suggest
little additional benefit of inhibiting caspase-1 over blockade of IL-
1 signaling, other effects on epithelial cells cannot be excluded as
IL-18R expression can be detected on the cells (Figure S1A). IL-
18 would also be expected to affect other cells in the infected lung,
potentially priming neutrophils [32,33] and enhancing effector
function of NK, CD4 and CD8 T cells [34]. Evidence that IL-18
may act on alternative inflammatory cells is supported by Kang et
al (15), who showed that IL-18R2/2 mice were protected from
lung damage and inflammation initiated by tobacco smoke plus
poly I:C or infection with influenza virus.
Although we show significant extracellular active IL-1b and IL-
18, we also clearly demonstrate the presence of extracellular pro-
IL-1b and pro-IL-18 after viral infection of cells. Therefore we
cannot rule out that released pro-IL-1b and pro-IL-18 can also
play a part in host response, via processing to active cytokines by
extracellular proteases in vivo.
In addition to IL-1b and IL-18, we described IL-1a release
following HRV infection of epithelial cells, the first report of this to
our knowledge. IL-1a has been portrayed as a key signal of
dysregulated cell death [21], due to its ability to be biologically
active without cleavage and its additional intracellular functions.
However, in this instance release of IL-1a appeared to be an active
process, since inhibition of HRV-induced cytotoxicity failed to
inhibit its release. Unlike the release of active IL-1b and IL-18
upon HRV infection, IL-1a release was not affected by the
inhibitor YVAD, therefore its release was not dependent upon the
catalytic activity of caspase-1. A recent study in myeloid cells
shows that IL-1a may be actively processed intracellularly and
secreted in an inflammasome-dependent or -independent fashion,
depending on the nature of the stimulus [35]. Our findings that
HRV infection triggers caspase-1 dependent IL-1b release and
concomitant caspase-1 independent IL-1a release suggest that the
findings of Groß et al may be more broadly applicable and merit
further investigation in this context. Our data do indicate that
conventional caspase-1 inhibitors, or antibodies targeting individ-
ual IL-1RI- activating cytokines may not be the optimal approach
to inhibit IL-1 signaling in this situation, given that rhinovirus is
capable of producing not only physiologically relevant levels of IL-
1b, but also IL-1a, and there may be potential impact of
extracellular cleavage of released pro-forms of IL-1b.
The signaling pathways downstream of HRV recognition have
been shown to involve members of the interferon regulatory family
(IRF) as well as NFkB and AP-1 (17). The resulting signaling leads
to the transcription of genes belonging to the IFN pathway and of
genes encoding various pro-inflammatory mediators respectively.
In addition to the production of IL-1 and IL-18 we also observed
the release of other pro-inflammatory mediators such as IL-6 and
IL-8 as shown in previous studies [9]. At the low MOI used,
although we detected an accumulation of mRNA encoding
mediators belonging to the IFN pathway, there was only minimal
or no release of interferon proteins into the media, although IP-10
which has been shown to be downstream of IRF signaling [36],
was detectable.
We found that inhibition of IL-1RI during HRV infection using
recombinant IL-1ra obliterated the production of IL-6 and IL-8,
but not IP-10. These data are in accordance with recent
observations in epithelial cell lines from Stokes et al showing that
in immortalised epithelial cells (BEAS-2B) autocrine IL-1 signaling
was likely to be contributing to HRV-induced cytokine production
[24], and also the reported dependence of IP-10 induction on
autocrine or paracrine effects of type I IFN produced by epithelial
cells and monocytes during HRV infection [37]. Addressing a
wider range of mediators by measuring upregulation at the gene
level, we confirmed that several mediators considered to be pro-
inflammatory were inhibited by blockade of IL-1RI but such
inhibition was not observed for IFNs or IFN-inducible genes,
confirming the pattern observed at the protein levels. MyD88
signaling has been reported to have the potential to negatively
regulate IFN-signaling in HRV infection [38], but we saw no
evidence IL-1RI mediated signaling was a major modifier of IFN
responses in HRV-infected primary cells.
Blockade of IL-1 signaling for the duration of the HRV
infection had no effect on viral titers in infected NHBE cells.
Taking this together with the maintained IP-10 and IFN
responses, it is unlikely inhibition of IL-1RI signaling mediates
its effects by downregulation of ICAM-1 and reduced viral
infection. Importantly, Stokes et al previously reported that
knockdown of MyD88 resulted in increased viral replication in
HRV-infected BEAS-2B cell line [33]. The difference in this
observation may reflect either differences between primary cells
and cell lines, or more likely that MyD88 knockdown will also
modulate TLR signaling which may have additional effects
beyond modulation of the IL-1 pathway.
In an experimental model of exacerbations in humans, when
COPD patients were challenged with rhinovirus, a clear causal
relationship was demonstrated between viral infection and
exacerbation of disease [7]. Rhinovirus infection was temporally
associated with a significant and sustained neutrophil influx and
increased levels of neutrophil elastase and IL-8 in the sputum of
subjects with COPD. There were strong correlations between
sputum neutrophil elastase levels and severity of symptoms and
airflow obstruction exclusively in subjects with COPD, not in
subjects matched for smoking history but without COPD. In
addition, virus load correlated significantly with neutrophil
numbers and inflammatory mediators in serum, sputum, and
BAL. Therefore, therapies that reduce or normalise neutrophil
response to viral infection without reducing anti-viral responses
could be beneficial in reducing the severity of AECOPD, although
appropriate consideration of potential effects on bacterial host
defence in colonised patients would be required. Given the
neutrophil influx is rapid in response to infection, and in patients a
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viral infection only becomes evident on onset of symptoms, any
such therapy likely would require prophylactic administration for
maximum efficacy, although some benefit of treatment at onset of
symptoms may be evident if the sustained neutrophil influx is
important in severity and/or duration of symptoms. Although we
have studied the impact of IL-1RI blockade in HRV responses of
epithelial cells without assessing the impact on other structural or
tissue-associated cells in the lung, our data could suggest that in the
context of a virally-triggered exacerbation of COPD, blocking IL-
1 signaling may translate into a decreased inflammatory response,
e.g. lung neutrophilia, with limited effect on the induction of anti-
viral mediators downstream of the IFN pathway and the
recruitment of effectors involved in the adaptive immune response
such as CD8 T cells. This has not been addressed in vivo with
rhinovirus, however IL-1R12/2 mice infected with influenza
virus demonstrated a decreased lung neutrophilia and pulmonary
inflammation compared to wild type mice [39]. In this model, IL-1
signaling was found to be important for the priming of virus-
specific CD4 T cells but, at the peak of the lymphocyte response,
the number of influenza virus specific cytotoxic T cell responses
was comparable in wild type and IL-1R12/2 and the virus titer
only moderately increased in the latter. Smoke exposure can also
exacerbate the response to influenza A virus in mice, and IL-1R
deficiency has been shown to attenuate exacerbated neutrophilic
responses in smoke-exposed influenza-infected animals [40].
Interestingly, this effect could be recapitulated with an anti-IL-
1a antibody, while IL-1RI2/2 and anti-IL-1a-treated mice did
not suffer from an increase in viral burden.
Updated new guidelines from regulatory agencies suggest
modification or prevention of exacerbations is an acceptable key
aim of new medicinal products for the treatment of COPD. Given
the importance of common viruses in induction of exacerbations in
chronic respiratory disease further study of inhibition of the IL-1
pathway should be undertaken. Given the data presented here
showing their combined involvement in HRV infection, agents
that block both IL-1a and IL-1b, such as IL-1RI antagonists, may
be appropriate as an anti-inflammatory in the treatment of COPD
exacerbations. A phase II clinical study with an IL1R antagonist
(NCT01448850) is currently underway in patients with COPD
that should further clarify the potential role of this pathway in
human respiratory disease.
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Figure S1 IL-18 receptor expression and inhibitory
activity of IL-18BP. (A) NHBE cells from 2 separate donors
were labelled with the indicated anti IL-18R antibody or isotype
control. The data shows the mean fluorescent intensity (MFI).
Representative staining is shown from 2 independent experiments.
(B) KG-1 cells were treated with or without 10ng/mL rIL-18 in
the presence of the indicated inhibitor (2 indicates no treatment,
IL-18BP and the control IgG were both used at 33nM). Following
a 24 hour incubation the release of IFNc into the medium was
measured by ELISA. The data shows mean +/2 SD (n=1).
(TIF)
Figure S2 Mediator release at different MOI of virus.
NHBE cells were infected with HRV14 at the indicated MOI.
After the indicated time the levels of IL-1b (A) and IL-8 (B)
released into the media was measured by ELISA. The data is from
a representative experiment and shows mean +/2 SD mediator
release.
(TIF)
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